Efficacy
MAY
By the data cutoff date on May 9, 2023, the median follow-up for the 40 response-evaluable patients was 25.9 months (interquartile range [IQR] = 22.7–30.0). Twenty-eight had a confirmed objective response (two achieved complete response and 26 achieved partial response), with an objective response rate (ORR) of 70% (95% CI = 53.5–83.4%; Fig. 